EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

TPX2 overexpression promotes sensitivity to dasatinib in breast cancer by activating YAP transcriptional signaling

Carlos Marugán iD, Natalia Sanz-Gómez iD, Beatriz Ortigosa, Ana Monfort-Vengut iD, Cristina Bertinetti, Ana Teijo, Marta González, Alicia Alonso de la Vega iD, María José Lallena, Gema Moreno-Bueno iD, Guillermo de Cárcer iD

Molecular Oncology · 2024

DOI: 10.1002/1878-0261.13602 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Oncology, 2024. Verfasst von Carlos Marugán und 10 weiteren Autor:innen. Beteiligte Einrichtung: Cell Cycle & Cancer Biomarkers Laboratory, Cancer Department, Instituto de Investigaciones Biomédicas Sols-Morreale (IIBM) CSIC-UAM, Madrid, Spain. Hauptthemen laut MEDLINE: Dasatinib, Breast Neoplasms, Proto-Oncogene Mas, YAP-Signaling Proteins. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 111 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Spanish National Research Council (CSIC), Ministerio de Ciencia, Innovación, Agencia Estatal de Investigación MCIN/AEI/FEDER, Instituto de Salud Carlos III - CIBERONC.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chromosomal instability (CIN) is a hallmark of cancer aggressiveness, providing genetic plasticity and tumor heterogeneity that allows the tumor to evolve and adapt to stress conditions. CIN is considered a cancer therapeutic biomarker because healthy cells do not exhibit CIN. Despite recent efforts to identify therapeutic strategies related to CIN, the results obtained have been very limited. CIN is characterized by a genetic signature where a collection of genes, mostly mitotic regulators, are overexpressed in CIN‐positive tumors, providing aggressiveness and poor prognosis. We attempted to identify new therapeutic strategies related to CIN genes by performing a drug screen, using cells that individually express CIN‐associated genes in an inducible manner. We find that the overexpression of targeting protein for Xklp2 ( TPX2 ) enhances sensitivity to the proto‐oncogene c‐Src (SRC) inhibitor dasatinib due to activation of the Yes‐associated protein 1 (YAP) pathway. Furthermore, using breast cancer data from The Cancer Genome Atlas (TCGA) and a cohort of cancer‐derived patient samples, we find that both TPX2 overexpression and YAP activation are present in a significant percentage of cancer tumor samples and are associated with poor prognosis; therefore, they are putative biomarkers for selection for dasatinib therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DasatinibBreast NeoplasmsProto-Oncogene MasYAP-Signaling ProteinsTranscription FactorsAdaptor Proteins, Signal TransducingCell Cycle ProteinsMicrotubule-Associated ProteinsSignal TransductionHumansFemaleCell Line, TumorGene Expression Regulation, NeoplasticNuclear ProteinsPhosphoproteinsDrug Resistance, Neoplasm

Stichwörter der Autor:innen

Hippo‐YAP/TAZSFK kinasesTPX2chromosomal instabilitydasatinibmitosis

Substanzen

DasatinibProto-Oncogene MasMAS1 protein, humanYAP-Signaling ProteinsTranscription FactorsAdaptor Proteins, Signal TransducingYAP1 protein, humanCell Cycle ProteinsTPX2 protein, humanMicrotubule-Associated Proteins

Autor:innen und Institutionen

  • Cell Cycle & Cancer Biomarkers Laboratory, Cancer Department, Instituto de Investigaciones Biomédicas Sols-Morreale (IIBM) CSIC-UAM, Madrid, Spain.
  • Discovery Chemistry Research and Technology, Eli Lilly and Company, Madrid, Spain.
  • Translational Cancer Research Laboratory, Cancer Department, Instituto de Investigaciones Biomédicas Alberto Sols-Morreale (IIBM) CSIC-UAM, Madrid, Spain.
  • Pathology Department, MD Anderson Cancer Center, Madrid, Spain.
  • MD Anderson International Foundation, Madrid, Spain.
  • Biomedical Cancer Research Network (CIBERONC), Madrid, Spain.

ORCID-Profile: Carlos Marugán, Natalia Sanz-Gómez, Ana Monfort-Vengut, Alicia Alonso de la Vega, Gema Moreno-Bueno, Guillermo de Cárcer

Förderung

  • Spanish National Research Council (CSIC)
  • Ministerio de Ciencia, Innovación, Agencia Estatal de Investigación MCIN/AEI/FEDER
  • Instituto de Salud Carlos III - CIBERONC
  • Spanish Association Against Cancer (AECC) Scientific Foundation
  • Consejo Superior de Investigaciones Científicas
  • Fundación Científica Asociación Española Contra el Cáncer

Zitieren

APA

Marugán, C., Sanz-Gómez, N., Ortigosa, B., Monfort-Vengut, A., Bertinetti, C., Teijo, A., González, M., Alonso de la Vega, A., Lallena, M. J., Moreno-Bueno, G., & de Cárcer, G. (2024). TPX2 overexpression promotes sensitivity to dasatinib in breast cancer by activating YAP transcriptional signaling. Molecular Oncology. https://doi.org/10.1002/1878-0261.13602

Vancouver

Marugán C, Sanz-Gómez N, Ortigosa B, Monfort-Vengut A, Bertinetti C, Teijo A, et al. TPX2 overexpression promotes sensitivity to dasatinib in breast cancer by activating YAP transcriptional signaling. Molecular Oncology. 2024. doi:10.1002/1878-0261.13602

BibTeX
@article{Marugn2024,
  author = {Marugán, Carlos and Sanz-Gómez, Natalia and Ortigosa, Beatriz and Monfort-Vengut, Ana and Bertinetti, Cristina and Teijo, Ana and González, Marta and Alonso de la Vega, Alicia and Lallena, María José and Moreno-Bueno, Gema and de Cárcer, Guillermo},
  title = {TPX2 overexpression promotes sensitivity to dasatinib in breast cancer by activating YAP transcriptional signaling},
  journal = {Molecular Oncology},
  year = {2024},
  doi = {10.1002/1878-0261.13602}
}
Kostenlos starten →